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Abstract
Background: Many studies have been published on the mutational status of patients with lung adenocarcinomas,
and great population-based variability in mutation frequencies has been reported. The main objective of the
present study was to analyze the EGFR, KRAS and ALK mutation status in a representative cohort of patients in
Croatia with lung adenocarcinomas and to correlate the mutational status with clinical data.
Methods: All patients who were newly diagnosed within 6 months with histologically proven primary lung
adenocarcinomas were included. Mutational analyses for EGFR and KRAS mutations were performed in a cobas z
480 analyzer. ALK immunohistochemistry was performed using the D5F3 clone on Benchmark XT instrument.
Clinical data were obtained from the medical records.
Results: Of the 324 patients, 59.9 % were male. At the time of diagnosis, the patients ranged in age range from 35
to 88 years (median 63 years). Most of the patients were current smokers or former smokers (77.2 %). EGFR
mutations were found in 15.7 % of the patients, and of these mutations, exon 19 deletion was the most common
(45.1 %). KRAS mutations were present in 34.9 % of the patients, while 4.1 % of patients were ALK-positive. The
statistical significance of the presence of mutations was detected for both gender and smoking.
Conclusion: The detected mutation rates demonstrated a slightly higher prevalence of KRAS mutations, but not a
higher prevalence of EGFR mutations or ALK gene rearrangement, in comparison with the rates found in other
European countries. EGFR and ALK mutational status showed a statistically significant correlation with gender as
well as with smoking, while KRAS mutation status showed a statistically significant correlation only with smoking.
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Background
In the last decade, great improvements have been made in
the development of targeted therapies for lung cancer. To
date, all approved targeted therapies have been aimed at
adenocarcinomas of the lung, with adequate targets
detected. Since patients with lung carcinoma usually
present in an advanced stage, and the amount of available
tissue is limited, it can be very difficult to reach a diagnosis
and preserve sufficient tissue for molecular testing.
Molecular testing for epidermal growth factor receptor
(EGFR) and anaplastic lymphoma kinase (ALK) muta-
tions should be a current standard in pathology practice.
The prevalence of EGFR mutations varies among differ-
ent populations, and these mutations are present in
higher frequencies in women, in light or never-smokers
and in East Asian patients [1–7]. Patients with specific
mutations in the EGFR gene will respond differently to
tyrosine kinase inhibitor (TKI) therapy. Patients with
EGFR-mutated lung cancers have a better prognosis
compared with patients without mutations, regardless of
therapy type [8]. ALK gene rearrangement, which is
another targetable genetic change in lung adenocarcin-
omas, was discovered in 2007 [9]. The frequency of ALK
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rearrangements is approximately 5 % in lung adenocarcin-
omas [9, 10] and is higher in light or never-smokers and
in younger individuals [11–13]. Mutations in Kirsten rat
sarcoma viral oncogene homolog (KRAS) are the most
common mutations in lung adenocarcinomas, but cur-
rently, no targeted therapy is available. According to some
studies, KRAS mutations are more prevalent in women,
but other reports found no difference in regards to gender
[14–16]. Mutations in EGFR, ALK and KRAS are gener-
ally regarded as mutually exclusive [8, 10, 11, 17].
The aim of this study was to present the EGFR,
KRAS and ALK mutations in a representative cohort
of patients with lung adenocarcinomas in Croatia and
to correlate the mutational status with clinical data.
Methods
Patients
This study was was performed at the University of Zagreb
School of Medicine, Department of Respiratory Diseases
Jordanovac, and the Institute of Pathology, Zagreb, Croatia.
All patients who underwent routine bronchoscopy proce-
dures or surgery for the diagnosis or treatment of lung
carcinoma from 1.5.2014 to 1.11.2014, as well as those who
were diagnosed with lung adenocarcinomas, adenosqua-
mous carcinomas or non-small cell lung carcinomas not-
otherwise specified (NSCLC-NOS) were included. The 7th
edition of the Union for International Cancer Control
(UICC) TNM classification criteria were used for staging.
A smoker was defined as a patient who has smoked at least
100 cigarettes in a lifetime and is still smoking, a former
smoker was defined as a patient who has smoked at least
100 cigarettes in a lifetime, but is currently not smoking,
and a never-smoker was defined as a patient who has never
smoked or who has smoked fewer than 100 cigarettes in a
lifetime. Diagnostic procedures were performed according
to the proposed 2011 adenocarcinoma classification by the
International Association for the Study of Lung Cancer/
American Thoracic Society/European Respiratory Society
[18], using additional immunohistochemistry when needed,
either the residual section of formalin fixed paraffin em-
bedded (FFPE) tissue, or May-Grünwald Giemsa (MGG)
stained cytological smears or frozen unstained smears,
were submitted for molecular testing.
Mutational analyses
Samples were tested in a sequential order; first for EGFR
mutations, followed by KRAS testing of EGFR-negative
samples and ALK rearrangement testing of EGFR- and
KRAS-negative samples.
EGFR and KRAS mutational analyses
DNA was extracted from FFPE tissue samples and
cytological samples, and sometimes macrodissection
was performed to ensure a content of at least 10 %
tumor. DNA was extracted using a cobas DNA Sample
Preparation Kit (Roche Diagnostics GmBH, Mannheim,
Germany) according to the package inserts. The meas-
urement of the DNA quantity was performed using a
Nanodrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). Samples were
tested by polymerase chain reaction (PCR) in a cobas z
480 analyzer (Roche Diagnostics GmBH, Mannheim,
Germany) using the cobas EGFR Mutation Test, which
can detect 41 mutations in exons 18, 19, 20 and 21 of
the EGFR gene, and the cobas KRAS Mutation Test
(both Mutation Tests purchased from Roche Diagnos-
tics, GmBH, Mannheim, Germany), which can detect
mutations in codons 12, 13, and 61.
ALK immunohistochemistry
The analysis of the tumors for ALK gene rearrange-
ment was performed by immunohistochemistry on a
Benchmark XT instrument (Ventana Medical Systems,
Tucson, AZ) using the Ventana ALK antibody clone
D5F3 (Roche Diagnostics GmBH, Mannheim, Germany)
with the OptiView detection kit (Roche Diagnostics
GmBH, Mannheim, Germany). The results were scored as
either positive or negative according to the manufacturer’s
recommendations.
Statistical analysis
Associations between gender, smoking status, Eastern
Cooperative Oncology Group (ECOG) performance
status and mutation status were tested using Pearson’s
chi square test. Associations between age at diagnosis,
T stage, N stage, M stage, clinical stage and mutation
status were tested using Wilcoxon’s rank sum test.
Confounding risk factors were eliminated by stratification
using the Cochran-Mantel-Haenszel method. Logistic
regression was used in order to test for the interaction of
gender and smoking status with respect to mutation
status. R 3.2.3 was used for all calculations. P values less
than 0.05 were considered statistically significant.
Results
Clinical data
In the designated 6-month period, all together 332
patients were newly diagnosed with adenocarcinomas
(320), adenosquamous carcinomas [1] or NSCLC-NOS
[11]. Of these samples, adequate material for EGFR test-
ing was available for 324 patients, while 8 samples from
patients with NSCLC-NOS were not further evaluated
due to insufficient tissue or poor DNA quality. Resected
tissue from 69 patients (69/324, 21.3 %) was available,
while for the remaining patients (255/324, 78.7 %), bi-
opsies/cytological samples were used. Due to sequential
testing, the time from sample arrival at the molecular
laboratory to EGFR mutation analysis was, on average,
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8 working days. For KRAS analysis, the total turn-
around time was 11 working days, and for ALK re-
arrangement analysis, the turnaround time was as high
as 25 working days.
In all, 194 males (194/324, 59.9 %) and 130 females
(130/324, 40.1 %) were included in the analysis. The age at
diagnosis ranged from 35 – 88 years for males (median
62 years) and from 39 – 86 years for females (median
64.5 years). The number of smokers and former smokers
was higher in the male population (170/194, 87.6 %), as
only 80/130 (61.5 %) females were smokers or former
smokers. The majority of the patients were in clinical
stage IIIB and IV (222/324, 68.5 %), followed by stages II-
IIIA (63/324, 19.5 %) and stage I (26/324, 8.0 %) (Table 1).
EGFR mutation analysis
In the entire group of 324 patients, 51 patients (15.7 %)
had EGFR mutations. The most common were exon 19
deletions (23/51, 45.1 %), followed by the exon 21 point
mutation L858R (20/51, 39.2 %), the exon 18 point
mutation G719X (4/51, 7.8 %), and exon 20 insertions
(2/51, 3.9 %). In addition, two patients had more than
one mutation, one of which was a resistance mutation
(G719X+ S768I in a male patient, a former smoker;
L858R + T790M in a female patient, a never-smoker).
The types of EGFR mutations are presented in Table 2.
The distribution of EGFR mutations according to gender
showed a high predominance in the female group, where
40/130 (30.8 %) had EGFR mutations, the most common
of which were exon 19 deletions (21/40, 52.5 %). In
comparison, 11/194 patients (5.7 %) in male subgroup had
EGFR mutations, of which L858R was the most common
(6/11, 54.5 %). The highest incidence of EGFR mutations
was observed in never-smokers (regardless of gender) 32/
74 (43.2 %), was much lower in former smokers, 11/103
(10.7 %) and was lowest in smokers (8/147, 5.4 %). The
most common mutations in smokers and former smokers
were exon 19 deletions (5/8, 62.5 % and 4/11, 36.4 %, in
smokers and former smokers, respectively). The associa-
tions between the presence of EGFR mutations and either
gender (p < 0.0001) or smoking status (p < 0.0007) were
demonstrated to be statistically significant. In female
never-smokers (50 patients), 26 had EGFR mutations (26/
50, 52 %), while only seven of 57 female smokers had
EGFR mutations (7/57, 12.3 %). Interestingly, of 23 female
former smokers, seven female former smokers (7/23,
30.4 %) had EGFR mutations. No statistically significant
differences were observed between the presence of mu-
tations and the wild type genotype with respect to
ECOG, T stage, N stage, M stage, clinical stage, or type
of material used for testing. The difference between
genders remained significant after stratification by
smoking status (p < 0.0001), and the differences be-
tween smoking status remained significant after stratifi-
cation by gender (p < 0.0001). The interaction between
smoking and gender was not statistically significant
according to logistic regression (p = 0.38).
KRAS mutation analysis
EGFR-negative patients (273 in all) were further tested
for KRAS mutations. KRAS mutations were detected in
113 (41.4 %) patients in this “enriched” group. The great
majority (107/113 patients; 94.7 %) had mutations in
codons 12/13, and 6/113 (5.3 %) had mutations in codon
61 (five of these patients were smokers or former
smokers). KRAS mutations were more frequent in males
Table 1 Summary of clinical and molecular-pathological characteristicsa
TOTAL EGFR KRAS ALK
wt mut wt mut wt mut
324 (100)
Age (range, median) 35-88, 63
Gender
Male 194 (59.9) 183 (94.3) 11 (5.7) 97 (53.6) 84 (46.4) 80 (97.6) 2 (2.4)
Female 130 (40.1) 90 (69.2) 40 (30.8) 61 (67.8) 29 (32.2) 40 (80.0) 10 (20.0)
Smoking status
Smokers 147 (45.4) 139 (94.6) 8 (5.44) 75 (54.3) 63 (45.7) 65 (95.6) 3 (4.4)
Former smokers 103 (31.8) 92 (89.3) 11 (10.7) 49 (53.8) 42 (46.2) 37 (97.4) 1 (2.6)
Never-smokers 74 (22.8) 42 (56.8) 32 (43.2) 34 (81) 8 (19) 18 (69.2) 8 (30.8)
Clinical stageb
I 26 (8.0) 22 (8.1) 4 (7.8) 8 (5.1) 11 (9.2) 7 (5.8) 0 (0)
II-IIIA 63 (19.5) 51 (18.7) 12 (23.5) 31 (19.6) 20 (16.8) 28 (23.3) 1 (8.3)
IIIB-IV 222 (68.5) 190 (69.6) 32 (62.7) 112 (70.9) 76 (63.9) 79 (65.8) 10 (83.3)
Legend: adata presented as absolute numbers and percentages in parentheses; wt wild type, mut mutated, b for 12 patients no data for clinical stage were
available; numbers in bold indicate a statistically significant difference
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(84/181, 46.4 %) than in females (29/90, 32.2 %) and
were very common in smokers (63/138, 45.7 %) and
former smokers (42/91, 46.2 %) compared with never-
smokers (8/42, 19 %), regardless of gender (Table 2).
The correlation between KRAS mutational status and
smoking status (p = 0.0053) and between KRAS muta-
tional status and gender (p = 0.026) proved to be statisti-
cally significant. No statistically significant differences
were found between mutations and the wild type geno-
type with respect to age, ECOG, T stage, N stage, M
stage, clinical stage or type of material used for testing.
The difference between genders was not significant after
stratification by smoking status (p = 0.11). However, the
differences between smoking status remained significant
after stratification by gender (p = 0.016). The interaction
between smoking and gender was not statistically signifi-
cant according to logistic regression (p = 0.98).
ALK gene rearrangement testing
ALK immunohistochemical analysis was performed in
the 160 EGFR- and KRAS-negative patients. Testing was
successful in samples from 82 males and 50 females. In
28 samples, there was insufficient material for further
analyses. In males, 2/82 (2.44 %) had ALK gene rear-
rangements, while in females, 10/50 patients (20 %) were
demonstrated to have ALK-positive rearrangement based
on strong immunohistochemical reaction. The highest
incidence of ALK gene rearrangement was observed in
never-smokers (8/26, 30.8 %), followed by a very low in-
cidence in smokers (3/68, 4.4 %) and former smokers (1/
38, 2.6 %) (Table 2). These correlations between ALK
status and gender (p < 0.0001) as well as between ALK
status and smoking status (p = 0.0007) were also statisti-
cally significant. No statistically significant differences
were observed between the presence of mutations and
wild type genotype with respect to age, ECOG, T stage,
N stage, M stage, clinical stage or type of material
used for testing. The difference between genders
remained significant after stratification by smoking
status (p = 0.0082), and the differences between smok-
ing status remained significant after stratification by
gender (p = 0.0031). The interaction between smoking
and gender was not statistically significant according
to logistic regression (p = 0.52)
Since genetic changes in EGFR, KRAS and ALK are
practically mutually exclusive, we can conclude that in
our study group of 324 patients, 51 had EGFR muta-
tions (15.7 %), 113/324 had KRAS mutations (34.9 %),
and, of the 296 patients with enough material for im-
munohistochemical analysis of ALK translocations, 12
were positive (4.1 %) (Additional file 1: Table 1).
Discussion
We presented the results of the EGFR, KRAS and ALK
mutational analyses in patients with lung adenocarcin-
omas in a prospective study, regardless of clinical stage.
The analyses were performed only on patients who were
newly diagnosed during a 6-month period at a single insti-
tution in Croatia. Importantly, the Department of Respira-
tory Diseases Jordanovac at the University Hospital
Centre Zagreb is a referral center for lung diseases, and
the majority of patients with lung carcinoma (almost
60 %) are diagnosed and treated here. According to avail-
able data from the Croatian National Cancer Registry for
2014, the number of patients with newly diagnosed carcin-
oma of the lung was 2915, and, of those, 1693 were diag-
nosed in our department (1693/2915, 58.1 %) [19]. To
date, this is the largest, most representative study of the
mutational status of Croatian patients with lung adenocar-
cinomas. Our population was composed primarily of
males (59.9 %) and a high proportion of smokers and
former smokers (77.2 %); this population is practically
identical to that of the recently published INSIGHT Study
[20] and is also similar to those in other studies [21, 22].
In many published studies, a wide range in the preva-
lence of EGFR mutations has been reported in lung
carcinomas, from 7.5 % in Norway [23, 24], 8.8 % in a
mixed ethnic population in the USA [10], to 10 to 15 %
in Europe [20, 22], to more than 50 % in Asian countries
[25, 26]. In the study by Zaric et al., the authors detected
the presence of EGFR mutations in 11.7 % of their pa-
tients [22], while the INSIGHT Study showed a preva-
lence of 13.8 % of EGFR mutations in patients with lung
carcinomas [20]. Our prevalence of 15.7 % in EGFR-
mutated lung adenocarcinomas seems to be among the
higher rates in European countries and is closer to what
was reported in the Russian study by Moiseyenko, where
the prevalence was 19.8 % [27].
Table 2 Distribution of EGFR, KRAS and ALK mutations
according to gender and smoking statusa
Gender Smoking status
M F S F N
EGFR mutations present 11 40 8 11 32
Exon 19 deletion 2 21 5 4 14
L858R 6 14 2 4 14
G719X 1 3 1 1 2
Exon 20 insertions 1 1 0 1 1
G719X + S768I 1 0 0 1 0
L858R + T790M 0 1 0 0 1
KRAS mutations present 84 29 63 42 8
Codon 12/13 79 28 59 41 7
Codon 61 5 1 4 1 1
ALK translocation 2 10 3 1 8
Legend: aData presented as absolute numbers. M male, F female, S smoker, F
former smoker, N never-smoker, numbers in bold indicate a statistically
significant difference
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What might be the reason for such a difference?
There are some very important, and usually neglected
differences, between published studies in regards to pa-
tient selection criteria (clinical and pathological), as
well as the methods used for mutational analysis. In a
French study by Vallee et al., one of the largest studies
in Europe, [28] 1403 tumor samples were analyzed, of
which 1144 were adenocarcinomas and 101 were
NSCLC-NOS; EGFR mutations were found in 14.7 %
and 4.0 %, of adenocarcinomas and NSCLC-NOS, re-
spectively. They used fragment analysis for exon 19
deletions and allele-specific PCR to detect the L858R
mutation. Other mutations were not explored, and thus
the true incidence of EGFR mutations in this population
is almost certainly a bit higher than reported. Milella et al.
presented the results of patients in clinical stages IIIB and
IV, with histologically heterogeneous tumors (125 adeno-
carcinomas, 17 squamous cell lung carcinoma and 46
other lung carcinomas) [21]. They also analyzed only exon
19 deletions and the exon 21 point mutation, and reported
that 9.0 % of patients had EGFR mutations, but 40.4 % of
their patient population was unable to be evaluated. Even
when we analyzed what was apparently the lowest re-
ported rate of EGFR mutations (7.5 %) in a study in
Norway [23], we see that, of 240 tumors, only 141 were
actually lung adenocarcinomas, and only 11 % of patients
had EGFR mutations. The patients included in that study
all had operable lung cancers, and the investigators used a
TheraScreen EGFR mutation kit (DxS, Manchester, UK)
to detect 28 specific mutations; some samples were fur-
ther analyzed by denaturing high-performance liquid
chromatography and sequencing. In a more recent study
in Norway, the prevalence of EGFR mutations in lung
adenocarcinomas was found to be 9.4 % [24]. However,
the INSIGHT Study, which comprises results form 6
central European countries each with different inclusion
criteria and testing methods, analyzed 1785 patients, of
whom 1393 were diagnosed with adenocarcinomas [20].
The prevalence of EGFR mutations in patients with
adenocarcinomas was 15.4 %, which was practically identi-
cal to our findings. A Russian study analyzed only lung
adenocarcinomas, which were assessed by PCR in a Cycler
iQ Real Time Detection System (Bio Rad Laboratories,
GmBH, Munich, Germany); the results revealed a preva-
lence of EGFR mutations that was higher compared with
that in other European countries (19.8 %) [27], but was
still lower than that in Asian populations, in which the
prevalence is above 40 %. In one study in China, the au-
thors reported EGFR mutations in 66.3 % of consecutively
collected lung adenocarcinomas, which were analyzed by
sequencing [25]. Another interesting point in the com-
parison of our results with those of the INSIGHT study
was the frequency of specific mutations; while practically
no differences were observed in the frequency of exon 19
deletions (the most common mutation type) and exon 20
insertions, the frequency of the L858R mutation was
higher in our patients (representing 39.2 % of all muta-
tions compared with 28.3 % in the INSIGHT Study) [20].
To date, only one study with data on EGFR mutations in a
Croatian population was published. This study, by Mohar
et al., reported a prevalence of EGFR mutations of 19.8 %
in tested patients [29]. However, in this paper, the authors
analyzed only cytological samples that were obtained from
more than one hospital, and it is not clear from the paper
whether the analysis was performed with or without pa-
tient pre-selection. Another possible reason for the differ-
ence between the reported prevalence rates and our
results might be the higher number of female patients
(53.9 % compared with 40.1 % in our study).
However, in all the studies presented here, and in
practically all others, a statistically significant correlation
was found between gender and EGFR status (mutations
are more prevalent in females) and between smoking
and EGFR mutation status (mutations are more preva-
lent in never smokers and former smokers). This is in
accordance with our results. It is known that higher
EGFR mutation frequencies are observed in female, non-
smoking patients of Asian origin [25, 26], reaching more
than 60 % in this population. A similar, higher EGFR
mutation frequency (52 %) was also found by our study
group when only females who are non-smokers were
analyzed. The limitation of this finding is that the num-
ber of these patients was relatively low (50 patients), but
nevertheless, the similarity is obvious.
KRAS mutations are present in many different tu-
mors, including carcinomas of the lung, as KRAS is
one of the most commonly mutated genes in human
cancer [30]. In lung carcinomas, KRAS mutations are
more common in smokers [31–33]. KRAS mutations
occur in approximately 30 % of lung adenocarcinomas
in Caucasians [30, 34–36] and in approximately 10 %
of lung adenocarcinomas in Asians [34, 37]. To date,
no effective therapy that targets KRAS has been released,
although some therapeutic molecules are currently under
investigation [38]. In lung adenocarcinomas, mutations
usually occur in codon 12 of exon 2, followed by codon 13
of exon 2 (3-5 %) and rarely (<1 %) in codon 61 of exon 3
[39]. Interestingly, in a Chinese population composed of
patients with lung adenocarcinomas who are also
smokers, the incidence of KRAS mutations was found to
be 14.0 %, while that of non-smokers was 3.4 % [40]. Two
studies of Asian patients with NSCLC [41, 42], as well as
meta- and pooled analyses [43, 44], demonstrated that the
presence of KRAS mutations is a poor prognostic factor
in Asians with NSCLC, while its relationship to prognosis
in cases of NSCLC in non-Asian patients is still debatable.
Additionally, the predictive role of KRAS mutations is not
yet completely clear (for review see [45]). Our results
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demonstrated a slightly higher incidence of KRAS mu-
tations in lung adenocarcinomas than was previously
reported for a Caucasian population, which might be
due to the smoking habits of this Croatian population.
Furthermore, in our population, the correlation of
KRAS mutations with smoking proved to be statistically
significant even after stratification for gender, which
was not the case for the correlation of KRAS mutations
with gender after stratification for smoking. The distri-
bution of specific types of mutations in our sample was
also similar to previously published data.
At the other end of the mutational landscape of lung
adenocarcinomas are ALK gene rearrangements, which
occur in 1-6 % of NSCLCs worldwide [46–48]. The
meta-analysis conducted by Fengzhi Zhao et al., which
included a total of 6950 patients, showed that the preva-
lence of ALK translocations was 6.8 % in NSCLC pa-
tients; this study did not select for ethnicity, but once
again demonstrated that ALK translocations are practic-
ally mutually exclusive with EGFR and KRAS mutations
[49]. They did find that EGFR and ALK alterations oc-
curred simultaneously in 15/6950 patients (0.2 %). Their
meta-analysis showed, for the first time, a higher fre-
quency of ALK gene rearrangement in a non-Asian
population (8.5 %, 173/2044) without selection for NSCLC,
compared with 6.1 % (299/4906) in an Asian population.
In a study by Wong et al., the prevalence of ALK gene
rearrangement in an East Asian population was 5 % [48].
By contrast, Fu et al. found 44 patients with ALK gene re-
arrangement, (43/382, 11.3 % of patients with lung adeno-
carcinoma, and 1/73, 1.3 % of patients with squamous cell
lung carcinoma) [50]. The prevalence of ALK gene re-
arrangement in the Chinese population also differs based
on smoking status, as the prevalence is lower in smokers
(2.9 %) than in non-smokers (7.2 %) (for review see 42).
Based on the fact that IHC and FISH are highly con-
cordant [51, 52], and that IHC was economically feas-
ible, we decided to test the tumors of our patients by
IHC only. Our IHC results are in agreement with pub-
lished results, as are their correlation with gender
(higher frequency in females) and smoking status
(lower frequency in former smokers and smokers).
Smoking and the higher percentage of males in our
study group are also the likely causes of the lower inci-
dence of ALK translocations in our population.
Although only 2.4 % of the initial number of pa-
tients who were eligible for molecular analysis did
not have adequate tissue/tumor cells for any tests, no
additional adequate material was available for ALK
immunohistochemistry in 8.6 % of the tested samples,
which stresses the importance of proper handling of
tumor samples in order to have enough for all neces-
sary analyses. This is an important issue that will
probably be solved by the introduction of panel tests,
in which not only can mutations be analyzed simul-
taneously, but a smaller amount of material is needed
for molecular testing.
Conclusion
In spite of the considerable published data on the preva-
lence of EGFR mutations in lung cancer throughout the
world, only a few papers present data on EGFR, KRAS
and ALK mutations in countries from Central Europe. By
contrast, based on the available data, it is usually difficult
to determine the actual prevalence of mutations in lung
adenocarcinomas since many selection biases occur.
These biases primarily concern the clinical stage (patient
selection for testing), the histological heterogeneity of the
tumors in which mutations are reported, and the testing
platforms that are used, which each have a different range
of detected mutations. Here, for the first time, we have
presented representative data for Croatian patients with
lung adenocarcinomas, and we demonstrate a higher
prevalence of the specific L858R mutation in the EGFR
gene, as well as a higher prevalence of KRAS mutations.
By contrast, we show that ALK gene rearrangement was
in the range of previously published data compared with
data from other European countries. Interestingly, while
the mutational status of EGFR and ALK was statistically
and significantly correlated with gender as well as with
smoking status, KRAS mutations showed a statistically
significant correlation only with smoking.
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